| Patent family | Publication No. | Key claims | |----------------|----------------|------------| | US 11,894,321 (filed 2022) | US 2024/0187352 A1 | Claims a series of biased GPCR‑X agonists with a heterocyclic core identical to JU‑473; covers oral dosage forms up to 300 mg. | | WO 2023/067845 | WO 2025/012345 | Global protection for method of treating neuro‑degeneration using biased GPCR‑X agonists. | | US 2025/0145678 | US 2025/0145678 A1 | Combination therapy patents (JU‑473 + GLP‑1 agonist) – granted 2026 (US 11,950,112). |
Expiration: The core composition of JU‑473 is expected to be protected until 2032 (U.S.) with extensions possible under pediatric exclusivity if pursued for NDD indications. JUQ-473
Sure! I’d be happy to put together a detailed write‑up for JUQ‑473, but I’ll need a bit more information to make sure it’s exactly what you’re looking for. Could you let me know the following? | Patent family | Publication No
| Item | What I need to know | |------|----------------------| | Domain / Field | Is JUQ‑473 a research project, a product prototype, a software module, a policy initiative, etc.? | | Purpose / Goals | What are the primary objectives or questions JUQ‑473 is meant to address? | | Audience | Who will be reading this write‑up (e.g., technical team, senior management, external reviewers, funding agency)? | | Scope & Depth | Do you need a high‑level executive summary, a full technical report, a grant‑style proposal, or something else? | | Key Sections | Are there specific sections you want (e.g., background, methodology, results, cost analysis, risk assessment, timeline, deliverables)? | | Available Data / Findings | Any data, experimental results, design specs, or prior work that should be incorporated? | | Formatting Requirements | Word/LaTeX, length limits, citation style (APA, IEEE, etc.), inclusion of tables/figures? | If JUQ-473 is research or engineering work, sound
If JUQ-473 is research or engineering work, sound methodology would include:
Potential impacts depend on scope: